Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017-2023

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2024-11-13 DOI:10.1093/cid/ciae560

Elena Ferran, Cathleen Chan, Noorann Sheikh, Martin Dedicoat, Eliza Alexander, Ana Gibertoni-Cruz, James Brown, Esther Robinson, Marc Lipman

引用次数: 0

Abstract

Fluoroquinolones are an important component of anti-tuberculosis treatment and identifying fluoroquinolone resistance is essential. We present the first survey of fluoroquinolone resistance in England from sequencing of over 16,000 unselected isolates. Fluoroquinolone resistance was 1.4% overall and 23.9% in multidrug-resistant TB. Routine sequencing allows resistance surveillance and should be widely adopted.

查看原文本刊更多论文

通过全基因组测序药物预测 2017-2023 年英格兰结核分枝杆菌复合分离株中氟喹诺酮类药物耐药性的人群水平频率

氟喹诺酮类药物是抗结核治疗的重要组成部分，因此识别氟喹诺酮类药物的耐药性至关重要。我们通过对 16,000 多份未经选择的分离株进行测序，首次对英格兰的氟喹诺酮类药物耐药性进行了调查。氟喹诺酮类药物的耐药性在总体上占 1.4%，在耐多药结核病中占 23.9%。常规测序可对耐药性进行监测，应得到广泛采用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.